🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Latest issue of Bone Marrow Transplantation, a consensus paper on QC harmonization for 🇪🇺 locally-manufactured #CAR-T_cells rdcu.be/eostD Ibrahim Yakoub-Agha The EBMT ASH FOCIS International Union of Immunological Societies SFI Immunologie Monica Guzman Immunopaedia Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx Mohamad Mohty

So what steps can trialists, regulators, journals, editors, reviewers, sponsors & academics take to improve toxicity reporting + identification? 👇check out this figure from our The Lancet Haematology adverse event commission thelancet.com/journals/lanha… Surbhi Sidana, MD Mohamad Mohty

Proud of Prof Ali Bazarbachi, a newly elected member of the national academy of medicine in France - Mohamad Mohty Dr. Fadlo Khuri oncodaily.com/url/304323 #OncoDaily #Oncology #Cancer #Health #Medicine

IACH News of the week. June 1, 2025. 🗞️ IACH Mohamad Mohty Topics: • VEXAS • MRD & MM • ALL • Fitness (ELNet) • FDA ODAC • New book: “Hoffbrand” 8th edition. ✍🏻

ISB-2001 continues to impress with further updates Targeting BCMAxCD38xCD3, ORR was 79%! 71% refractory to cd38; 46% with prior BCMA therapies Grade 3+ infection rate 29%. CRS mostly grade 1. Durability data not available but looking good at 6 months so far.

📄 [Press release] – MaaT Pharma is proud to announce the submission of the Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (registered brand name of MaaT013) in Acute Graft-versus-Host Disease. ✅ If approved, Xervyteg® would be the

Happening TOMORROW register for FREE Bhagirath Dholaria, MD Matthew Frigault Mohamad Mohty

Join us TODAY at 6pm CET FREE REGISTRATION ⬇️⬇️ us06web.zoom.us/webinar/regist… Mohamad Mohty

The power of cellular immunotherapy ! Impressive results! Congratulations ! ⁦Journal of Clinical Oncology⁩ ⁦IACH⁩ ⁦COMy⁩ ⁦ASCO⁩

And a new era of MRD-guided personalized therapy… NEJM IACH COMy IUCT Oncopole Congratulations Aurore Perrot nejm.org/doi/abs/10.105…

We are LIVE! IACH for Patients part of the Multiple Myeloma Academy: My Story and Advocacy Efforts Register for FREE ⬇️⬇️ us06web.zoom.us/webinar/regist… Mohamad Mohty

Amazing response rates with trispecific antibody JNJ-5322 in RR MM. N. van de Donk suggest it is as effective as BCMA targeting CART. In fections are still quite high. All patients should get prophylactic IgG replacement. 12 months PFS of 95%. Prophylactic toci significantly

Wow- #NEJM- Hot off the presses! This large (and nicely designed), phase 3, multi-arm study evaluated Isa+KRd and used an MRD guided consolidation strategy in transplant eligible patients. Great work, Mohamad Mohty and the MIDAS investigators!

The On-Body Delivery System redefines care by putting treatment in motion, freeing patients from hospital chairs and giving them the comfort, control, and quality of life they truly deserve! ⁦Journal of Clinical Oncology⁩ ⁦IACH⁩ ⁦COMy⁩

👂Hear the latest IACH NEWS podcast: CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma by Dr. Alejandro Luna ⬇️⬇️ iach.org/iach-news-podc… Alejandro Luna Roni Shouval Mohamad Mohty Arnon Nagler

Happening 𝕋𝕆𝔻𝔸𝕐 IACH Journal Club: 𝗖𝘆𝗰𝗹𝗼𝗽𝗵𝗼𝘀𝗽𝗵𝗮𝗺𝗶𝗱𝗲 𝗠𝗶𝘁𝗶𝗴𝗮𝘁𝗲𝘀 𝗡𝗼𝗻-𝗜𝗖𝗔𝗡𝗦 𝗡𝗲𝘂𝗿𝗼𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝗶𝗲𝘀 𝗙𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗖𝗶𝗹𝘁𝗮𝗰𝗮𝗯𝘁𝗮𝗴𝗲𝗻𝗲 𝗔𝘂𝘁𝗼𝗹𝗲𝘂𝗰𝗲𝗹 𝘑𝘰𝘪𝘯 𝘋𝘳. 𝘉𝘩𝘢𝘨𝘪𝘳𝘢𝘵𝘩𝘣𝘩𝘢𝘪 𝘋𝘩𝘰𝘭𝘢𝘳𝘪𝘢,

𝐖𝐞 𝐚𝐫𝐞 𝐋𝐈𝐕𝐄! IACH Journal Club: Cyclophosphamide Mitigates Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel Register for 𝔽ℝ𝔼𝔼 ⬇️⬇️ us06web.zoom.us/webinar/regist… Bhagirath Dholaria, MD Matthew Frigault Mohamad Mohty